Alkermes

Yahoo Finance • 10 days ago

Alkermes Starts Phase 3 Orexin Trials As Narcolepsy Story Builds

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Alkermes (NasdaqGS:ALKS) has started Phase 3 Brilliance Studies fo... Full story

Yahoo Finance • 12 days ago

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story

Yahoo Finance • 12 days ago

Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the growing interest in the orexin receptor agon... Full story

Yahoo Finance • 2 months ago

Alkermes plc Q4 2025 Earnings Call Summary

Alkermes plc Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Portfolio Evolution Management characterizes 2025 as a pivotal year, transitioning from a royalty-based technology company to a proprietary products business... Full story

Yahoo Finance • 2 months ago

Alkermes Q4 Earnings Call Highlights

Alkermes logo Key Points Alkermes reported nearly $1.5 billion in 2025 revenue (proprietary sales ≈ $1.2B) and GAAP net income of $241.7M, but after closing the Avadel deal it guides 2026 to total revenue of $1.73–1.84B with a 2026 GAAP... Full story

Yahoo Finance • 2 months ago

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026

DUBLIN, February 11, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 25, 2026 to discuss the company’s fourth quarter and year-end 2... Full story

Yahoo Finance • 2 months ago

Pharma companies left out of Trump's drug-pricing deals look for way in

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentiall... Full story

Yahoo Finance • 2 months ago

MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA

Moderna MRNA shares plunged around 10% in after-hours trading following the announcement that the FDA’s Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the biologics license application (BL... Full story

Yahoo Finance • 2 months ago

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

Avadel Pharmaceuticals plc NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, F... Full story

Yahoo Finance • 3 months ago

Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference

DUBLIN, December 30, 2025--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The... Full story

Yahoo Finance • 4 months ago

Why Analysts are Rating Alkermes (ALKS) a Buy

Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50. At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS). The stock has been covered by 15 analys... Full story

Yahoo Finance • 4 months ago

Announcement relating to despatch of Rule 15 proposal

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RU... Full story

Yahoo Finance • 4 months ago

Avadel (AVDL) Drops 6.7% on Lack of Leads

We recently published 10 Stocks Losing Their Bite Before Thanksgiving. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the worst-performing stocks on Wednesday. Avadel declined by 6.67 percent on Wednesday to end at $21.40 apiece as in... Full story

Yahoo Finance • 5 months ago

Alkermes raises Avadel buyout offer after Lundbeck’s unsolicited bid

[M&A Mergers And Acquisitions] narvo vexar Alkermes (ALKS [https://seekingalpha.com/symbol/ALKS]) has raised its buyout offer for Avadel Pharmaceuticals (AVDL [https://seekingalpha.com/symbol/AVDL]), indicating a price of up to $22.50 per... Full story

Yahoo Finance • 5 months ago

Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION DUBLIN, Nov. 19, 2025 /PRNewswire/ -... Full story

Yahoo Finance • 5 months ago

Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOU... Full story

Yahoo Finance • 5 months ago

Avadel (AVDL) Gets 26% Boost on Takeover Bid

We recently published 10 Market Movers That Made Millionaires in a Week. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks of the past trading week. Avadel jumped by 26.06 percent week-on-week as investors load... Full story

Yahoo Finance • 5 months ago

Can Alkermes (ALKS) Overcome Modest Differentiation to Lead in Narcolepsy Treatment Innovation?

Alkermes recently reported positive topline results from its Vibrance-2 phase 2 study of alixorexton in patients with narcolepsy type 2, with the therapy meeting both primary efficacy endpoints and showing a generally well-tolerated safety... Full story

Yahoo Finance • 5 months ago

Avadel (AVDL) Soars to 10-Year High on Brewing Bidding War

We recently published Lackluster Market? Not for These 10 Soaring Stocks. Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the best-performing stocks on Friday. Avadel extended its winning streak to a 5th straight day on Friday to hit a... Full story

Yahoo Finance • 5 months ago

Avadel Receives Unsolicited Proposal from Lundbeck

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOU... Full story